Lp(a)
Lipoprotein(a) – genetically determined cardiac risk marker
Also known as
Definition
Lipoprotein(a) is an LDL-like particle carrying an additional apolipoprotein(a) moiety and is strongly genetically determined. Elevated Lp(a) levels are an independent, causally established risk factor for myocardial infarction, stroke, and aortic valve stenosis. Because Lp(a) is largely unresponsive to lifestyle changes, testing primarily serves risk stratification and treatment decision-making.
| Parameter | Value |
|---|---|
| Unit | mg/dl (nmol/l) |
| Reference Range | < 50 mg/dl (< 125 nmol/l) per ESC guidelines 2019 |
| Optimal Range (lab2go) | < 30 mg/dl (low risk) |
Lp(a) is measured in mg/dl (mass) or nmol/l (particle number) — both units are not directly interchangeable because particle size varies. ESC threshold: < 50 mg/dl or < 125 nmol/l. International studies increasingly prefer nmol/l.
↓ What a low value means
Lp(a) below 30 mg/dl is considered low risk and is cardiovascularly favorable. Since Lp(a) is ~80–90% genetically determined, a low value reflects a favorable genetic profile, not a lifestyle achievement. Clinically there is no lower limit for Lp(a).
↑ What a high value means
Lp(a) 30–50 mg/dl: moderate risk, dependent on other cardiovascular risk factors. Lp(a) > 50 mg/dl: elevated independent risk for heart attack, stroke, and aortic valve stenosis. Lp(a) > 180 mg/dl: very high risk, equivalent to heterozygous familial hypercholesterolemia. Lp(a) is causally established in atherosclerosis (Mendelian Randomization). Risk doubles for heart attack above 50 mg/dl.
✓ How to optimize this marker
Because Lp(a) is genetically determined, no established lifestyle measures exist to lower it. PCSK9 inhibitors lower Lp(a) by ~20–25% (as a side benefit). Niacin lowers Lp(a) by 20–30% but is rarely recommended today due to side effects. Novel RNA-based therapies (pelacarsen, olpasiran) in Phase 3 trials show > 80% reduction. With elevated Lp(a), aggressively control all other cardiovascular risk factors.
When to test
A single measurement in adulthood is sufficient (genetically stable). ESC recommends once-in-a-lifetime screening, especially with family cardiovascular history, premature atherosclerosis, heart attack with normal cholesterol, or treatment-refractory hypercholesterolemia. No fasting required. Lp(a) does not change significantly with age or diet.
Frequently asked questions
Can I lower elevated Lp(a) with diet or exercise? +
Barely. Because Lp(a) is 80–90% genetically determined, diet and exercise have only minimal influence (< 5–10%). Conditions such as hypothyroidism or kidney insufficiency can raise Lp(a) secondarily and should be treated. The focus should be on controlling other risk factors.
How often do I need to have Lp(a) measured? +
Once is enough. Lp(a) is stable throughout adult life and barely changes with lifestyle or aging. Repeat measurement is only useful with conditions that can secondarily raise Lp(a) (hypothyroidism, nephrotic syndrome).
What does elevated Lp(a) mean for my treatment plan? +
Elevated Lp(a) increases overall cardiovascular risk and influences LDL targets: ESC guidelines recommend tightening the LDL target by one category when Lp(a) is elevated. Strict control of all other risk factors (blood pressure, smoking, blood glucose, LDL) is the most important practical consequence.
Sources
Last Reviewed: May 28, 2026 · sina
This information is for orientation only and does not replace medical advice. Reference ranges can vary by laboratory, method and country.